Showing results (2861-2870 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 6, 2019
Screening, identification of prostate cancer urinary biomarkers and verification of important spotsHuijun Zhao, Xuhong Zhao, Ting Lei, et al.
Investigational New Drugs|May 1, 1990
Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group studyE H Kraut, J J Crowley, M R Grever, et al.
Investigational New Drugs|November 3, 2006
Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiformeTom Mikkelsen, Richard Lush, Stuart A Grossman, et al.
Investigational New Drugs|February 1, 1991
Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinomaS R Patel, L K Kvols, J Rubin, et al.
Investigational New Drugs|March 10, 2007
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometryJ H Beumer, R C Garner, M B Cohen, et al.
Investigational New Drugs|September 20, 2006
Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II studyStefan von Delius, Florian Eckel, Stefan Wagenpfeil, et al.
Investigational New Drugs|January 5, 2007
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Liangli Zhao, Elaine S Marshall, Lloyd R Kelland, et al.
Investigational New Drugs|June 23, 2007
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortiumM J Mackenzie, D Saltman, H Hirte, et al.
Investigational New Drugs|July 26, 2006
Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell linesYasuhiko Kano, Miyuki Akutsu, Saburo Tsunoda, et al.
Investigational New Drugs|June 23, 2006
A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145Michael J Kovacs, Donna E Reece, Deborah Marcellus, et al.
Pageof 372